Novocure-Zai announce MAA approval for Optune to treat GBM patients

Date: 2020-05-15   Author: Saipriya Iyer  Category: #news

Novocure-Zai announce MAA approval for Optune to treat GBM patients

Novocure and Zai Lab Ltd. have recently announced the MAA (Marketing Authorization Application) approval from the China NMPA (National Medical Products Administration). The approval has been given for the use of Optune, in combination with temozolomide, to treat newly diagnosed GBM (glioblastoma) patients. It will also be used as a monotherapy for patients suffering from recurrent GBM. Optune is the 1st treatment for GBM that has been approved in over 15 years in China.

According to Dr. Samantha Du, Zai Lab’s CEO, Chairperson, and Founder, the recent approval is a significant treatment advancement for GBM patients in China and an important milestone for the company. Optune has previously been granted with the Innovative Medical Device Designation. It highlights the importance and differentiation of this novel treatment for patients with GBM. The company appreciates NMPA for this thorough and rapid assessment of the application of Optune, which will help serve high unmet medical needs. Dr. Du further stated that the company is looking forward to working with Novocure, to leverage Tumor Treating Fields and treat several cancer indications, including GBM.

William Doyle, Executive Chairman of Novocure, stated that the company is focusing on the commercialization and development of Tumor Treating Fields to increase the survival rate of several aggressive cancers. He also expressed appreciation towards their partner, Zai Lab, for collectively working to obtain Optune approval in Greater China.

Tumor Treating Fields therapy is delivered by Optune to the tumor region. It has been used to treat over 15,000 GBM patients to date, globally. The therapy has been approved by the FDA for the treatment of MPM (malignant pleural mesothelioma), which is expected to be the next Marketing Authorization Application filed with the China NMPA. It is also under Phase 3 pivotal trials to treat ovarian cancer, pancreatic cancer, non-small cell lung cancer, and brain metastases, and in Phase 2 pilot trials to treat gastric cancer and liver cancer. In China, over 1.5 million patients are diagnosed with gastric, ovarian, non-small cell lung, and pancreatic cancers, collectively in a year.

Source credit:https://www.businesswire.com/news/home/20200513005458/en/China-NMPA-Approves-Optune%C2%AE-Treatment-Newly-Diagnosed



About Author


Saipriya Iyer linkdin-boxtwitter

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

Post Recommendents

63 moons to offer next-gen tech to Spuma SRL in pan-European market expansion

Author: Saipriya Iyer

63 moons technologies, a world leader in providing next-generation technology platforms, has recently announced its plans to boost and back Italy-located Spuma SRL, with its next-generation technological abilities and ...


Global Joint Reconstruction Devices Market to Observe Strong Development during the Forecast Period 2021 to 2027

Author: Rahul Varpe

Global market insights declares the publication of its latest research report, with the title ‘global Joint Reconstruction Devices market’. This report sheds light on the analysis of the industry chall...


Surgical Robots Market is poised to grow at a Healthy CAGR between 2022 to 2030

Author: Rahul Varpe

Global market insights declares the publication of its latest research report, with the title ‘global Surgical Robots market’. This report sheds light on the analysis of the industry challenges, growth opportunities, industry threats, ...